Business Wire

Personalis, Inc. Announces Collaboration With Merck KGaA, Darmstadt, Germany, to Identify and Develop Novel Biomarkers for Cancer Therapies

Share

Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Darmstadt, Germany, will utilize Personalis’ newest cancer immunogenomics platform, ImmunoID NeXT™, for clinical biomarker identification and development.

ImmunoID NeXT, through innovative assays and analytics, provides a comprehensive view of each cancer’s genomics and immune microenvironment from a single, limited tumor sample. The platform is an end-to-end solution built for precision oncology biomarker discovery through to clinical applications, enabling simultaneous analysis of cancer mutations, the immune repertoire, neoantigens, tumor escape mechanisms, DNA repair pathways, human leukocyte antigens (including typing, loss of heterozygosity, and somatic mutation detection), tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, immune checkpoints, gene expression, immune signatures, and other advanced biomarkers.

“Merck KGaA, Darmstadt, Germany, is a global leader in cancer therapeutic development and we’re thrilled to collaborate with them to identify the next generation of clinical biomarkers for cancer therapies,” said Richard Chen, MD, CSO of Personalis. “We will work with Merck KGaA, Darmstadt, Germany, to leverage the NeXT Platform for novel biomarker identification, analysis of therapy resistance mechanisms, patient stratification, combination therapy strategy, and comprehensive molecular categorization of cancers for enabling precision therapy.”

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of € 14.8 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Contact information

Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678

Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Western Union and France’s La Banque Postale Expand Global Digital Payments28.1.2020 13:59:00 EETPress release

La Banque Postale, the banking subsidiary of France’s postal services’ operator, La Poste Group and one of France’s major banking networks with 10.3 million active customers today announced - as payment agent of Western Union - the expansion of global digital payment services, powered by Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments. The integration of Western Union’s global cross-border, cross-currency digital money movement platform within La Banque Postale’s mobile app and website will enable more than seven million online registered La Banque Postale customers to access Western Union’s international payment services and experience. La Banque Postale’s customers have the choice to fund their payments within the app or website using bank card and pay-out at Western Union’s Global Retail and Wallet Network. Western Union’s cross-border, cross-currency money movement platform – including global settlement capabilities, network, complianc

B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade28.1.2020 13:13:00 EETPress release

B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts, a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/ B2Broker Secures its Position as a PoP Liquidity Provider with Devexperts dxTrade (Photo: Business Wire) B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity poo

ADVA to play key role in OPENQKD project pioneering market-ready quantum-safe communications28.1.2020 11:00:00 EETPress release

ADVA (FSE: ADV) today announced that its FSP 3000 and FSP 150 platforms will play a pivotal role in the OPENQKD project. Leveraging its ConnectGuard™ technology, ADVA will provide optical and Ethernet encryptors as well as open line systems for multiple testbed locations. Funded by the European Commission, OPENQKD will create and trial a secure communication network across Europe based on quantum key distribution (QKD). The aim of the initiative is to accelerate the commercial adoption of QKD technology and to promote interoperability through an ecosystem of 38 partners, including academic institutions, network operators, and manufacturers of network and QKD equipment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005034/en/ ADVA's ConnectGuard™ technology is at the forefront of the OPENQKD project (Photo: Business Wire) “By bringing our technology and expertise to the OPENQKD project, we’re helping to address vital s

Lung Cancer Study Shows Barriers in Patient Access to Care in Europe28.1.2020 10:00:00 EETPress release

MSD, tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today presents preliminary results from a study carried out by The Economist Intelligence Unit (The EIU) on lung cancer, which show a fragmented policy approach across Europe. The study underlines that awareness needs to be addressed on multiple fronts to fight the stigma associated with this disease and to ensure patients receive timely access to the best possible care. The data were presented days before the European Commission’s official launch of the stakeholders’ consultation on Europe’s Beating Cancer Plan. “There is no room for complacency in lung cancer; 1 out of 5 of all cancer deaths in Europe is caused by lung cancer and it kills as many Europeans as breast, colon and prostate cancer combined. The study uncovers actionable solutions to empower countries and their health systems to better manage lung cancer, and ultimately, improve the lives of people living with a diagnosis of this treatable disease,” co

Teijin to Establish Teijin Automotive Center Europe to Expand Conceptual, Designing, Prototype and Evaluation Capabilities28.1.2020 04:31:00 EETPress release

Teijin Limited announced today that it would establish Teijin Automotive Center Europe GmbH (TACE) in Wuppertal, Germany in February as a new base for technical functions within the company’s automotive composite business. The company will handle concept, designing, prototyping, evaluations, marketing and technical research for next-generation automotive components, utilizing the Teijin Group’s capabilities to provide multi-material solutions for next-generation vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005758/en/ Envisioned demonstration and CAE experiments to be performed at TACE (Photo: Business Wire) TACE will enable Teijin to strengthen and advance its solution capabilities by establishing a strong platform for collaboration within the Teijin Group’s European automotive composite bases. It is expected to speed up concept, designing, prototyping and the evaluation of technological proposals developed

Rare Disease CDKL5 Deficiency Disorder Granted WHO Disease Classification27.1.2020 21:32:00 EETPress release

The rare genetic disease CDKL5 Deficiency Disorder (CDD) has been designated with a new disease code in the International Classification of Diseases (ICD), the medical classification list from the World Health Organization (WHO). The CDKL5 Deficiency Disorder diagnostic code will be incorporated in the October 1, 2020 classification revision. The medical classification, currently in its tenth revision (ICD-10), uses a list of alphanumeric codes to document a person’s medical condition. For example, a person with migraine headaches will receive the G43 code, and a person with type 2 diabetes the E11 code. These codes are then used for clinical research and care, and increasingly also for health insurance billing and reimbursement. According to the WHO, about 70% of the world’s health expenditures are allocated using ICD codes for reimbursement and resource allocation. There are many medical conditions that do not have a code in the international medical classification, and these disease

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom